2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 12:47, 15 September 2023
, 15 September 2023→Studies
No edit summary |
|||
| Line 93: | Line 93: | ||
| | | | ||
* randomized, placebo-controlled, double-blind | * randomized, placebo-controlled, double-blind | ||
* 10 | * 10 weeks | ||
* 250 mg/day | ** placebo (n=12) | ||
** 250 mg/day (n=13) | |||
| | | | ||
* 25 postmenopausal women with prediabetes | * 25 postmenopausal women with prediabetes | ||
* overweight or obese (BMI 25.3 - 39.1) | * overweight or obese (BMI 25.3 - 39.1) | ||
* 56 - 66 years | * 56 - 66 years | ||
| | | | ||
* increase in skeletal muscle insulin signaling, insulin sensitivity, and muscle remodeling | * increase in skeletal muscle insulin signaling, insulin sensitivity, and muscle remodeling | ||
* improvement in muscle insulin sensitivity is clinically relevant and is similar to the improvement observed after ~10% weight loss | * improvement in muscle insulin sensitivity is clinically relevant and is similar to the improvement observed after ~10% weight loss | ||
|- | |- | ||
|Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265078/</ref> | |||
| | | | ||
* randomized, double-blind, placebo-controlled | |||
* 6 weeks | |||
** baseline 0 mg/day (n=12) | |||
** small 300 mg/day (n=12) | |||
** medium 600 mg/day (n=12) | |||
** high 1200 mg/day (n=12) | |||
| | | | ||
* 48 young and middle-aged recreationally trained runners | |||
* 35 years in average | |||
| | | | ||
* he combination of NMN supplementation and exercise further improves ventilatory threshold even among healthy young and middle-aged people. | |||
* The improvement of aerobic capacity is in a dosage-dependent, large dosage of NMN with exercise has better effects. | |||
* The improvement is muscle, not cardiac, related. | |||
|} | |} | ||